Short answer
VERACYTE, INC. (VCYT) filed its Q2 2026 10-Q quarterly report on Jul 31, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $150M (up 15.5% year over year) with net income of $25M.
Q2 2026 key financials · XBRL
- Revenue
- $150M
- +15.5% YoY · +8.1% QoQ
- Net income
- $25M
- +2701.0% YoY · −11.2% QoQ
- Operating margin
- 15.3%
- Gross margin
- 72.2%
- EPS (diluted)
- $0.31
- +3200.0% YoY · −11.4% QoQ
Source: XBRL data from the VERACYTE, INC. (VCYT) Q2 2026 10-Q on SEC EDGAR. USD.
VERACYTE, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $150.3M, up $20.2M or 15% YoY; testing revenue $145.7M, up 19%
- Gross margin 72.2% vs 69.0% YoY; operating margin 15.3% vs (4.0)% YoY
- Testing revenue strongest line at $145.7M; biopharmaceutical and other revenue weakest at $0.8M, down 81%
- Diagnostic tests reported 48,389, up 14% YoY; total test volume 50,967, up 13%
- R&D expense $29.4M, up 81%; continued TrueMRD investment and payer utilization constraints as headwinds
Risk Factors
- No risk-factors section provided; submitted text contains only Items 2–6 and signatures
- Newly adopted insider trading plans covering 91,839 shares or net vested RSUs
- Director Karin Eastham’s plan covers 23,841 shares through May 7, 2027
- Director Muna Bhanji’s plan covers 3,728 shares through August 31, 2027
- Officer John Leite’s plan covers net shares from 44,270 RSUs vesting through August 13, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other VERACYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.